Revolution Medicines (NASDAQ:RVMD – Get Free Report) is scheduled to be releasing its earnings data after the market closes on Wednesday, November 6th. Analysts expect Revolution Medicines to post earnings of ($0.88) per share for the quarter.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.04). The firm had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $0.81 million. The company’s quarterly revenue was down 73.8% on a year-over-year basis. During the same period last year, the firm posted ($0.92) earnings per share. On average, analysts expect Revolution Medicines to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Revolution Medicines Trading Up 0.2 %
RVMD opened at $50.50 on Thursday. The firm has a market cap of $8.44 billion, a price-to-earnings ratio of -13.47 and a beta of 1.43. Revolution Medicines has a 12 month low of $18.00 and a 12 month high of $51.10. The stock has a fifty day moving average price of $45.59 and a 200-day moving average price of $42.18.
Wall Street Analyst Weigh In
Read Our Latest Analysis on Revolution Medicines
Insider Buying and Selling at Revolution Medicines
In other news, insider Stephen Michael Kelsey sold 16,666 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $49.49, for a total value of $824,800.34. Following the sale, the insider now owns 264,408 shares in the company, valued at $13,085,551.92. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Jack Anders sold 10,000 shares of Revolution Medicines stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $50.30, for a total transaction of $503,000.00. Following the completion of the transaction, the chief financial officer now directly owns 98,932 shares of the company’s stock, valued at $4,976,279.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Stephen Michael Kelsey sold 16,666 shares of Revolution Medicines stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $49.49, for a total transaction of $824,800.34. Following the transaction, the insider now directly owns 264,408 shares of the company’s stock, valued at approximately $13,085,551.92. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 127,866 shares of company stock worth $6,355,624. 8.00% of the stock is currently owned by insiders.
Revolution Medicines Company Profile
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
See Also
- Five stocks we like better than Revolution Medicines
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- What is a support level?
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
- Top Biotech Stocks: Exploring Innovation Opportunities
- Caterpillar Stock: Market Points to a Buying Opportunity
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.